K36 Therapeutics Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 14

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $70M

  • Investors
  • 5

K36 Therapeutics General Information

Description

Developer of small-molecule therapeutics designed to treat cancer through epigenetic modulation of oncogenic pathways. The company offers orally bioavailable small-molecule and selective NSD2 inhibitors, enabling healthcare professionals to treat cancer patients through targeted epigenetic therapy.

Contact Information

Website
www.k36tx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1 Main Street
  • 13th Floor
  • Cambridge, MA 02142
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 1 Main Street
  • 13th Floor
  • Cambridge, MA 02142
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

K36 Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series B) 28-Jun-2023 $70M Completed Clinical Trials - Phase 1
1. Early Stage VC (Series A) 28-Jan-2021 Completed Clinical Trials - Phase 1
To view K36 Therapeutics’s complete valuation and funding history, request access »

K36 Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A
To view K36 Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

K36 Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of small-molecule therapeutics designed to treat cancer through epigenetic modulation of oncogenic pathways. T
Drug Discovery
Cambridge, MA
14 As of 2026

Niel, Belgium
 

Maastricht, Netherlands
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

K36 Therapeutics Competitors (62)

One of K36 Therapeutics’s 62 competitors is etherna, a Formerly VC-backed company based in Niel, Belgium.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
etherna Formerly VC-backed Niel, Belgium
Cristal Therapeutics Venture Capital-Backed Maastricht, Netherlands
Centrose Venture Capital-Backed Madison, WI
Ayala Pharmaceuticals Corporation Wilmington, DE
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
You’re viewing 5 of 62 competitors. Get the full list »

K36 Therapeutics Patents

K36 Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026213567-A1 Piperidinyl-methylpurine pyridines and related compounds and their use in treating diseases and conditions Pending 04-Apr-2025
WO-2026213527-A1 Piperidinyl-methyl-purineamine nsd2 inhibitor therapeutic methods and compositions for treating cancer Pending 03-Apr-2025
US-20260159518-A1 Bridged heterobicyclic-methylpurine pyridines and related compounds and their use in treating diseases and conditions Pending 06-Dec-2024
WO-2026122815-A1 Deuterium-enriched piperidinyl-methyl-purine amine nsd2 inhibitor therapeutic methods and compositions for treating cancer Pending 04-Dec-2024
WO-2025259850-A1 Pharmaceutical compositions containing a deuterium-enriched piperidinyl-methyl-purine amine and their use in treating diseases and conditions Pending 12-Jun-2024 A61K31/52
To view K36 Therapeutics’s complete patent history, request access »

K36 Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

K36 Therapeutics Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bristol-Myers Squibb Corporation Minority
Nextech Invest Venture Capital Minority
Atlas Venture Venture Capital Minority
Eight Roads Corporate Venture Capital Minority
F-Prime Venture Capital Minority
To view K36 Therapeutics’s complete investors history, request access »

K36 Therapeutics FAQs

  • When was K36 Therapeutics founded?

    K36 Therapeutics was founded in 2021.

  • Where is K36 Therapeutics headquartered?

    K36 Therapeutics is headquartered in Cambridge, MA.

  • What is the size of K36 Therapeutics?

    K36 Therapeutics has 14 total employees.

  • What industry is K36 Therapeutics in?

    K36 Therapeutics’s primary industry is Drug Discovery.

  • Is K36 Therapeutics a private or public company?

    K36 Therapeutics is a Private company.

  • What is the current valuation of K36 Therapeutics?

    The current valuation of K36 Therapeutics is .

  • What is K36 Therapeutics’s current revenue?

    The current revenue for K36 Therapeutics is .

  • How much funding has K36 Therapeutics raised over time?

    K36 Therapeutics has raised $100M.

  • Who are K36 Therapeutics’s investors?

    Bristol-Myers Squibb, Nextech Invest, Atlas Venture, Eight Roads, and F-Prime have invested in K36 Therapeutics.

  • Who are K36 Therapeutics’s competitors?

    etherna, Cristal Therapeutics, Centrose, Ayala Pharmaceuticals, and Adaptimmune Therapeutics are some of the 62 competitors of K36 Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process